Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)

INTRODUCTION: For epidermal growth factor receptor mutation-positive (EGFRm) non-small-cell lung cancer (NSCLC), EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are the preferred first-line (1 L) treatment in the advanced setting. Osimertinib, a third-generation EGFR-TKI, received full approval in 2017...

Descripción completa

Detalles Bibliográficos
Autores principales: Addeo, Alfredo, Hochmair, Maximilian, Janzic, Urska, Dudnik, Elizabeth, Charpidou, Andriani, Płużański, Adam, Ciuleanu, Tudor, Donev, Ivan Shterev, Elbaz, Judith, Aarøe, Jørgen, Ott, René, Peled, Nir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842149/
https://www.ncbi.nlm.nih.gov/pubmed/35173817
http://dx.doi.org/10.1177/17588359211059874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842149/
https://www.ncbi.nlm.nih.gov/pubmed/35173817
http://dx.doi.org/10.1177/17588359211059874

Ejemplares similares